Christine P Hendon

The 5-year relative survival rate of women with endometrial cancer localized to the uterus is 96% and drops significantly to 71% if the cancer reaches regional organs and 20% if it metastasizes to distant organs. Screening for endometrial cancer is currently not part of clinical standard of care.

Dr. Christine Hendon, in collaboration with Drs. June Hou and Xiaowei Chen, aim to develop a transcervical hyperspectral imaging endoscope to screen for endometrial cancer. Funding for EQT will enable the generation of a database of spectral-based properties of the uterus, how it changes with disease presence, and prototype a hyperspectral imaging scope to show the proof of principle that spectral contrast has the potential to add diagnostically significant information when assessing the uterus for endometrial cancer surveillance. Screening with hyperspectral imaging technology can potentially decrease the time to diagnose endometrial cancer and identify it at its early stages, resulting in saved lives.